Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Zai Lab Ltd
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Manufacturing
Prev close 24.83 · gapped below the open, then crossed back over prior close. High/low 24.99 at 12:45 pm ET, 24.51 at 5:30 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In January 2025, Zenas BioPharma sublicensed their rights under the license agreement to Zai Lab and assigned the Manufacturing Development and Supply Agreement to Zai Lab in connection with the sublicense transaction.”
FILING10-K0001590750-26-000007cik 0001590750disclosed by VRDN
“agreement with NovoCure, pursuant to which we obtained an exclusive license under certain patents and know-how of NovoCure to develop and commercialize any Tumor Treating Fields (OPTUNE) products in all human therapeutic and preventative uses in the field of oncology in Greater China.”
FILING10-K0001704292-26-000015cik 0001704292
“license agreement with Seagen (a company later acquired by Pfizer), pursuant to which we obtained an exclusive license to develop and commercialize tisotumab vedotin (TIVDAK) in Greater China.”
FILING10-K0001704292-26-000015cik 0001704292
“In August 2025, the Company entered into a material transfer agreement ("MTA") with Zai Lab, to supply certain materials for clinical trial use.”
FILING10-K0001590750-26-000007cik 0001590750disclosed by VRDN
“Zai licensed povetacicept for mainland China, Hong Kong SAR, Macau SAR, Taiwan region, and Singapore, while Ono licensed povetacicept for Japan and South Korea.”
FILING10-K0000875320-26-000056cik 0000875320disclosed by VRTX
“license agreement with Deciphera, pursuant to which we obtained an exclusive license under certain patents and know-how of Deciphera to develop and commercialize products containing ripretinib (QINLOCK) in the field of prevention, prophylaxis, treatment, cure, or amelioration of any disease or medical condition in humans in Greater China.”
FILING10-K0001704292-26-000015cik 0001704292
“license agreement with MediLink, pursuant to which we obtained an exclusive global license to research, develop, manufacture, and commercialize MediLink's proprietary ADC targeting DLL3.”
FILING10-K0001704292-26-000015cik 0001704292
“license agreement with Turning Point (a company later acquired by BMS) pursuant to which we obtained an exclusive license to develop and commercialize products containing repotrectinib (AUGTYRO) as an active ingredient in all human therapeutic indications in Greater China.”
FILING10-K0001704292-26-000015cik 0001704292
“license agreement with Tesaro, a company later acquired by GSK, pursuant to which we obtained an exclusive sublicense under certain patents and know-how of GSK (including such patents and know-how licensed from Merck, Sharp & Dohme Corp.”
FILING10-K0001704292-26-000015cik 0001704292
“agreement with Entasis (now a wholly owned subsidiary of Innoviva), pursuant to which we obtained an exclusive license under certain patents and know-how of Entasis to develop and commercialize Entasis's proprietary compounds, durlobactam with sulbactam (the combination, SUL-DUR also known as XACDURO) with the possibility of developing and commercializing a combination of such compounds with imipenem in all human diagnostic, prophylactic and therapeutic uses in Greater China, Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand, and Japan.”
FILING10-K0001704292-26-000015cik 0001704292
Watchlist prices, news filtered to it, and its next report on your desk.
Zai Lab Ltd has 9 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Zai Lab Ltd’s own annual report or the counterparty’s, and carries the sentence that discloses it.
ZLAB (Zai Lab Ltd) has 9 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: VRDN −1.85%, in healthcare.